Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: Differential diagnosis between colonic and ovarian carcinomas as primary sites

Lagendijk, Jaap H.; Mullink, H.; Diest, Paul J. van; Meijer, Gerrit A.; Meijer, Chris J.L.M.

doi:10.1016/s0046-8177(98)90065-x

Cited by 174 publications

(97 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CK 7 and CK 20 antibodies are best used together in the differential diagnosis of a poorly differentiated carcinoma (13,17). When a carcinoma is CK 7ϩ/CK 20ϩ, the differential diagnosis should include pancreatic carcinoma, cholangiocarcinoma, transitional cell carcinoma, and intestinal-type sinonasal adenocarcinoma (36).…”

Section: Discussionmentioning

confidence: 99%

“…Studies have shown that the different expression patterns of CK 7 and CK 20 are among the most discriminant markers in: (1) the differential diagnosis between metastatic colon and ovarian adenocarcinomas (7,10,(12)(13)(14)(15)(16)(17); (2) the differential diagnosis between Merkel cell tumor of skin and small cell carcinomas of other origins (7, 11, 18 -21); and (3) the differential diagnosis between lung, endometrial, and breast adenocarcinomas and colon adenocarcinoma (20,22). Studies of CK 7 and CK 20 expression in other epithelial carcinomas have also been explored in the past ten years (11, 20 -22).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Cytokeratin 7 and Cytokeratin 20 Expression in Epithelial Neoplasms: A Survey of 435 Cases

2000

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Cytokeratin 7 and Cytokeratin 20 Expression in Epithelial Neoplasms: A Survey of 435 Cases

2000

View full text Add to dashboard Cite

“…These findings imply that evaluation of TTF-1 and CK 20 expression has limited clinical utility in the context of differentiating primary pulmonary from metastatic mucinous neoplasms. [29] …”

Section: Discussionmentioning

confidence: 99%

Expression of Thyroid Transcription Factor-1, Cytokeratin 7, and Cytokeratin 20 in Bronchioloalveolar Carcinomas: an Immunohistochemical Evaluation of 67 Cases

2002

View full text Add to dashboard Cite

“…5 In particular, the differential expression profile of various cytokeratin (CK) types by tumors at different primary locations can be essential in determining the origin of a malignant tumor. 1,2,4,[6][7][8] CKs are intermediate filament proteins and 20 subtypes have been classified based on isoelectric pH (focusing) and molecular weight. 5,[9][10][11] Two of the most used stains are CK20 and CK7.…”

mentioning

confidence: 99%

Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status

et al. 2008

View full text Add to dashboard Cite

The differentiation of colorectal cancer from primary tumors at other sites can be challenging. Often a panel of immunohistochemical protein markers is needed to distinguish between these entities. Protein expression differs significantly in colorectal cancer depending on mismatch repair status and is also heterogeneous among mismatch repair-proficient or -deficient tumors. The aim of this study was to systematically analyze the diagnostic and prognostic role of the commonly used multi-marker phenotype CK20/CK7/CDX2 on a large series of colorectal cancers stratified by mismatch repair status. The immunohistochemical analysis of CK20, CK7 and CDX2 was performed on 1197 mismatch repair-proficient and 223 mismatch repair-deficient colorectal cancers using a tissue microarray. Multi-marker combinations of CK20/CK7/CDX2 were explored. Univariate and multivariable analysis of the markers was evaluated for their association with several clinico-pathological end points namely T stage, N stage, tumor grade, vascular invasion, intratumoral lymphocytes and survival. Multimarker phenotypes with CK20 and CDX2 negativity were more frequently found in mismatch repair-deficient than in mismatch repair-proficient colorectal cancer (19.3 vs 7.5% and 21.6 vs 6.7%, respectively; Po0.001). In both colorectal cancer subsets loss of CK20 was associated with higher tumor grade (Po0.001) and with presence of intratumoral lymphocytes (Po0.001 and P ¼ 0.02, respectively). In the proficient mismatch repair subset CK20 overexpression was an independent adverse prognostic factor (P ¼ 0.041) and CDX2 underexpression was linked to tumor progression. Loss of CDX2 and CK20 is more frequently encountered in mismatch repair-deficient colorectal cancer, which should be taken into consideration to differentiate between primary and metastatic colorectal cancer in daily practice. Although associated with lower tumor grade, CK20 overexpression is an independent adverse prognostic factor in mismatch repair-proficient colorectal cancer.

show abstract

Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: Differential diagnosis between colonic and ovarian carcinomas as primary sites

Cited by 174 publications

References 12 publications

Cytokeratin 7 and Cytokeratin 20 Expression in Epithelial Neoplasms: A Survey of 435 Cases

Cytokeratin 7 and Cytokeratin 20 Expression in Epithelial Neoplasms: A Survey of 435 Cases

Expression of Thyroid Transcription Factor-1, Cytokeratin 7, and Cytokeratin 20 in Bronchioloalveolar Carcinomas: an Immunohistochemical Evaluation of 67 Cases

Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status

Contact Info

Product

Resources

About